Zobrazeno 1 - 8
of 8
pro vyhledávání: '"N Gastaut"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Le Pharmacien Hospitalier et Clinicien. 47:S5-S6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94247d12ba67f818f1ea7780511a50b8
https://doi.org/10.1016/j.phclin.2011.12.013
https://doi.org/10.1016/j.phclin.2011.12.013
Publikováno v:
European Journal of Hospital Pharmacy. 20:A192.2-A192
Background The purpose of labelling is to protect persons who take part to biomedical research. It must enable the product and study to be identified and the drugs to be used safely. The decree of 24 May 2006 [1] sets out the information to be includ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e90a0e1fc7a9e84b650f4dfb5edad4fe
https://doi.org/10.1136/ejhpharm-2013-000276.533
https://doi.org/10.1136/ejhpharm-2013-000276.533
Publikováno v:
European Journal of Hospital Pharmacy. 20:A204.2-A204
Background The sponsor is the person or entity that initiates a clinical trial, manages it and provides funding. We define two types of promoters, commercial sponsors and academic sponsors (mainly hospitals). In order to minimise the cost of academic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6641146ea442126f23e00080a4cce9c
https://doi.org/10.1136/ejhpharm-2013-000276.567
https://doi.org/10.1136/ejhpharm-2013-000276.567
Publikováno v:
European Journal of Hospital Pharmacy. 20:A190.2-A190
Background Good Clinical Practice specifies the role of the pharmacist in clinical trials. For each prescription dispensed for a named patient, the pharmacist is responsible for educating the patient on the treatment, counting any residual Investigat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b42249ce88a8a160ffd8affb88c153c
https://doi.org/10.1136/ejhpharm-2013-000276.527
https://doi.org/10.1136/ejhpharm-2013-000276.527
Publikováno v:
European Journal of Hospital Pharmacy. 20:A101.1-A101
Background Tocilizumab (TCZ) is an anti-IL-6 agent given as second-line biotherapy in the treatment of rheumatoid arthritis (RA). Guidelines for the prescription of TCZ indicate that it must be administered after anti-TNF-α failure at the University
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40dc45c9f079b2d9ddd9b6935cf35e88
https://doi.org/10.1136/ejhpharm-2013-000276.282
https://doi.org/10.1136/ejhpharm-2013-000276.282
Publikováno v:
European Journal of Hospital Pharmacy. 20:A16.2-A16
Background Around 3000 batches of medicinal products are prepared each year in Lapeyronie Hospital. For each batch, a batch file (BF) is created. This contains the prescription, a manufacturing and labelling sheet (MLS) and a control and batch releas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::249d1735b9ca7e7bcfe5d07b1b7856e2
https://doi.org/10.1136/ejhpharm-2013-000276.044
https://doi.org/10.1136/ejhpharm-2013-000276.044
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.